Quinn Emanuel Urquhart & Sullivan partners Kevin P.B. Johnson, Matthew Robson, Isaac Nesser and Sandra Haberny have stepped in to represent Genevant Sciences GmbH in a patent lawsuit related to materials used in Pfizer’s COVID-19 vaccine.
The suit was filed March 18 in New York Southern District Court by Acuitas Therapeutics Inc., which licenses a lipid nanoparticle for use in the Pfizer vaccine.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
